Vai al contenuto principale
Coronavirus: aggiornamenti per la comunità universitaria / Coronavirus: updates for UniTo Community
Oggetto:

Translational medicine in severe asthma

Oggetto:

Translational medicine in severe asthma

Oggetto:

Academic year 2020/2021

Teacher
Prof. Fabio Luigi Massimo Ricciardolo (Lecturer)
Teaching period
Da definire
Type
FAD
Credits/Recognition
1
Delivery
A distanza
Language
Inglese
Oggetto:

Sommario del corso

Oggetto:

Course objectives

Bronchial asthma is a complex and heterogeneous chronic inflammatory disorder of the airways with variable airflow obstruction. According to the Global Burden Disease Study, about 240 million people suffer from asthma worldwide, and in 2016 it caused 495.000 deaths. A subset of asthmatic patients (10-20%) has uncontrolled respiratory symptoms, with half of them being affected by severe asthma. Based on ATS/ERS expert panel consensus, severe asthma is defined as asthma requiring treatment with guideline suggested medications for GINA steps 4–5 asthma (high dose inhaled corticosteroid and long-acting beta-agonist or leukotriene modifier/theophylline) for the previous year or systemic corticosteroid for ≥50% of the previous year to maintain disease control. Severe asthma, despite affecting only 5-10% of asthmatics, is responsible for a large part of asthmarelated national healthcare costs. 

Despite a growing number of personalized therapeutic options are becoming available for severe asthmatic patients some of them still remain unresponsive or with partly controlled disease. This is in part a consequence of the great heterogeneity of the disorder, to such a degree that it is possible to identify several clinical, biological and pathophysiological phenotypes each of them underlined by specific molecular mechanisms (endotypes), which are responsible of a highly variable response of patients to therapies. Over the last years, several studies on large cohorts were performed to identify phenotype clusters, with the aim of developing personalized therapies. 

This course is focused on the description of the complexity and heterogeneity of this respiratory disorder, aiming to innovation and personalized therapy based on the principles of precision medicine.

Oggetto:

Program

  • Definition 
  • Diagnosis
  • Pathophysiology
  • Phenotypes
  • Endotypes
  • Pharmacological Therapy and Biologics
Oggetto:

Course delivery

Slides with power-point presentation, reviews and original articles (suggested readings).

At least 2 lessons (2 hours per lesson) and 2 meetings with students showing presentations concerning other model of precision medicine with personalized therapy (e.g. lung cancer and others).

Oggetto:

Learning assessment methods

Final test examinations

Suggested readings and bibliography



Oggetto:

Notes

15 Gennaio 2021 da ore 15 a ore 18 (eterogeneità e stratificazione);
22 Gennaio 2021 da ore 15 a ore 18 (fenotipi ed endotipi);
12 marzo 2021 da ore 15 a ore 18 (terapia personalizzata).

 

Enroll
  • Closed
    Enrollment opening date
    11/01/2021 at 18:00
    Enrollment closing date
    14/01/2021 at 12:00
    Oggetto:
    Last update: 18/01/2021 12:08
    Location: https://dott-mts-en.campusnet.unito.it/robots.html
    Non cliccare qui!